Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Hold” from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has received an average rating of “Hold” from the seven research firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $17.86.

Several equities research analysts recently issued reports on YMAB shares. HC Wainwright lifted their price target on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, May 13th. BMO Capital Markets lifted their price target on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a report on Monday, March 4th. Canaccord Genuity Group lifted their price target on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a report on Monday, March 4th. Finally, Truist Financial started coverage on shares of Y-mAbs Therapeutics in a report on Friday. They set a “buy” rating and a $21.00 price target on the stock.

Y-mAbs Therapeutics Stock Down 2.0 %

NASDAQ:YMAB opened at $12.08 on Monday. Y-mAbs Therapeutics has a 52 week low of $4.60 and a 52 week high of $20.90. The firm’s 50-day simple moving average is $13.07 and its 200 day simple moving average is $12.87.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Tuesday, May 7th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. The firm had revenue of $19.93 million during the quarter, compared to the consensus estimate of $22.06 million. Research analysts expect that Y-mAbs Therapeutics will post -0.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Thomas Gad sold 35,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $12.03, for a total transaction of $421,050.00. Following the sale, the insider now directly owns 197,681 shares in the company, valued at approximately $2,378,102.43. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Bo Kruse sold 31,371 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $12.07, for a total value of $378,647.97. Following the transaction, the chief financial officer now owns 210,877 shares in the company, valued at approximately $2,545,285.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas Gad sold 35,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $12.03, for a total transaction of $421,050.00. Following the completion of the transaction, the insider now owns 197,681 shares in the company, valued at approximately $2,378,102.43. The disclosure for this sale can be found here. Insiders have sold a total of 99,444 shares of company stock worth $1,203,925 in the last ninety days. Company insiders own 21.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of YMAB. Acadian Asset Management LLC increased its stake in shares of Y-mAbs Therapeutics by 24.0% in the 3rd quarter. Acadian Asset Management LLC now owns 811,261 shares of the company’s stock valued at $4,420,000 after acquiring an additional 157,173 shares in the last quarter. Trexquant Investment LP increased its stake in shares of Y-mAbs Therapeutics by 417.5% in the 3rd quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock valued at $417,000 after acquiring an additional 61,785 shares in the last quarter. GSA Capital Partners LLP increased its stake in shares of Y-mAbs Therapeutics by 208.3% in the 3rd quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock valued at $748,000 after acquiring an additional 92,765 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Y-mAbs Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 28,095 shares of the company’s stock valued at $192,000 after acquiring an additional 7,124 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Y-mAbs Therapeutics by 17.5% in the 4th quarter. SG Americas Securities LLC now owns 21,559 shares of the company’s stock valued at $147,000 after acquiring an additional 3,210 shares in the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.